Alkermes Plc (ALKS) Stock Price, Quote & News

Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed product...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 353 1 772 8000

Website: www.alkermes.com

Address:

Connaught House, 1 Burlington Road Dublin 4, Dublin, Ireland

Quantumup Dec. 1 at 1:25 PM

B.Riley⬆️ $CNTA's PT to $42 from $33 and reiterated at a Buy rating after Data Deep Dive $ALKS $TAK $AVDL $ESALY HRMY Here's what B.Riley had to say:

0 · Reply

Otus Nov. 26 at 7:47 PM

$ALKS I didn’t go all in here but I do have 5,200 shares. If the deal with avdl holds I think this will end up being a great multi year holding. If the deal holds I’ll probably go up to 10k shares.

0 · Reply

LarryYMB Nov. 26 at 6:37 PM

$ALKS this board is too boring , need some spice, it seems that the superior bid pushed away the danish fellas.

1 · Reply

prismmarketview Nov. 20 at 5:45 PM

(NASDAQ: $ALKS) (NASDAQ: $AVDL) #Alkermes has raised its offer to acquire #AvadelPharma to approximately $2.37 billion, increasing the offer to $22.50 per share, including $21.00 in cash plus a $1.50 contingent value right tied to FDA approval of Avadel’s narcolepsy drug Lumryz, after outbidding a rival offer from Lundbeck, with the deal expected to close in Q1 2026. https://prismmarketview.com/alkermes-raises-its-offer-to-acquire-avadel-in-2-3b-deal-focused-on-sleep-disorder-innovation/

0 · Reply

ZacksResearch Nov. 20 at 3:56 PM

Takeover drama just hit a new level 🔥 $ALKS lifting its bid to $22.50 per share to buy Avadel shifts the momentum hard, especially as the fight with Lundbeck heats up. See how this bidding war could play out 👉 https://www.zacks.com/stock/news/2793522/alks-raises-its-offer-to-buy-avadel-in-response-to-lundbecks-proposal?cid=sm-stocktwits-2-2793522-teaser-21864&ADID=SYND_STOCKTWITS_TWEET_2_2793522_TEASER_21864

0 · Reply

ZacksResearch Nov. 20 at 2:56 PM

$ALKS increases its offer for $AVDL — will Lundbeck up the ante? 💰 Alkermes has sweetened its bid to $22.50/share, valuing Avadel at $2.37B. With a Zacks Rank #1, this biotech battle is heating up! 🚀 Find out more about the bidding war here 👉 https://www.zacks.com/stock/news/2793522/alks-raises-its-offer-to-buy-avadel-in-response-to-lundbecks-proposal?cid=sm-stocktwits-2-2793522-body-21835&ADID=SYND_STOCKTWITS_TWEET_2_2793522_BODY_21835

0 · Reply

prismmarketview Nov. 19 at 3:07 PM

(Nasdaq: $AVDL) @AvadelPharma says Lundbeck’s $2.4B bid is “superior” to Alkermes’ (Nasdaq: $ALKS) offer, triggering a 5-day window for Alkermes to counter. Alkermes has already raised its proposal to $2.37B, setting up one of 2025’s biggest biotech bidding battles. https://prismmarketview.com/biotech-buyout-battle-royale-lundbecks-2-4b-bid-puts-pressure-on-alkermes-as-avadel-declares-offer-superior/

1 · Reply

LarryYMB Nov. 19 at 1:33 PM

$ALKS close the Avadel deal!

0 · Reply

OpenOutcrier Nov. 19 at 1:21 PM

$AVDL (-0.2% pre) $ALKS Alkermes increases Avadel acquisition offer to $22.50 per share https://ooc.bz/l/85063

0 · Reply

mikesterz7 Nov. 19 at 12:04 PM

$ALKS $AVDL Alkermes will now acquire Avadel for total transaction consideration of up to $22.50 per share.

0 · Reply

Alkermes to Participate in Two Upcoming Investor Conferences

Nov 19, 2025, 6:08 AM EST - 15 days ago

Alkermes raises offer for Avadel after Lundbeck bid

AVDL

Nov 19, 2025, 6:00 AM EST - 15 days ago

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

AVDL

Nov 17, 2025, 5:37 PM EST - 16 days ago

Alkermes plc (ALKS) Shareholder/Analyst Call Transcript

Nov 14, 2025, 11:37 AM EST - 20 days ago

Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal

AVDL

Nov 14, 2025, 9:40 AM EST - 20 days ago

H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal

AVDL

Nov 14, 2025, 8:17 AM EST - 20 days ago

Alkermes reviewing options after Lundbeck makes unsolicited bid for Avadel

AVDL

Nov 14, 2025, 7:45 AM EST - 20 days ago

Alkermes Response to Avadel Announcement

Nov 14, 2025, 5:45 AM EST - 20 days ago

Avadel Receives Unsolicited Proposal from Lundbeck

AVDL

Nov 12, 2025, 12:46 PM EST - 22 days ago

Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study

Nov 12, 2025, 7:35 AM EST - 22 days ago

Alkermes' narcolepsy drug meets main goal in a mid-stage trial

Nov 12, 2025, 7:30 AM EST - 22 days ago

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2

Nov 5, 2025, 9:00 AM EST - 4 weeks ago

FORM 8.1(a) & (b) (Opening Position Disclosure)

Nov 3, 2025, 9:58 AM EST - 4 weeks ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 28, 2025, 3:21 PM EDT - 5 weeks ago

Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 7:00 AM EDT - 5 weeks ago

Alkermes plc Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 4:52 PM EDT - 6 weeks ago

Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL

AVDL

Oct 22, 2025, 3:18 PM EDT - 6 weeks ago

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

AVDL

Oct 22, 2025, 10:53 AM EDT - 6 weeks ago

Alkermes plc (ALKS) M&A Call Transcript

Oct 22, 2025, 7:11 AM EDT - 6 weeks ago

Alkermes to acquire Avadel for up to $2.1 billion

AVDL

Oct 22, 2025, 7:00 AM EDT - 6 weeks ago

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc

AVDL

Oct 20, 2025, 4:00 PM EDT - 6 weeks ago

Alkermes to Report Third Quarter Financial Results on October 28, 2025

Sep 12, 2025, 9:00 AM EDT - 2 months ago

Alkermes Appoints Joshua Reed as Chief Financial Officer

Sep 11, 2025, 7:00 AM EDT - 3 months ago

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program

Sep 8, 2025, 2:34 PM EDT - 3 months ago

Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)

Sep 8, 2025, 3:15 AM EDT - 3 months ago

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

Aug 25, 2025, 7:00 AM EDT - 3 months ago

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025

Jul 30, 2025, 5:08 PM EDT - 4 months ago

Alkermes: A More Than Solid Quarter

Jul 29, 2025, 2:47 PM EDT - 4 months ago

Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 8:28 AM EDT - 4 months ago

Alkermes Q2 Sales Up 14 Percent

Jul 29, 2025, 7:00 AM EDT - 4 months ago

Alkermes plc Reports Second Quarter 2025 Financial Results

Jul 21, 2025, 6:00 AM EDT - 4 months ago

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

Jul 15, 2025, 4:00 PM EDT - 5 months ago

Alkermes to Report Second Quarter Financial Results on July 29, 2025

Jun 2, 2025, 4:00 PM EDT - 6 months ago

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 7:00 AM EDT - 6 months ago

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

May 1, 2025, 4:31 PM EDT - 7 months ago

Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible

May 1, 2025, 11:21 AM EDT - 7 months ago

Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 7 months ago

Alkermes plc Reports First Quarter 2025 Financial Results

Apr 30, 2025, 7:00 AM EDT - 7 months ago

New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)

Apr 17, 2025, 4:00 PM EDT - 8 months ago

Alkermes to Report First Quarter Financial Results on May 1, 2025

Apr 2, 2025, 4:00 PM EDT - 8 months ago

Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 8 months ago

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

Mar 27, 2025, 7:00 AM EDT - 9 months ago

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

Feb 26, 2025, 4:00 PM EST - 10 months ago

Alkermes to Participate in Upcoming Investor Conferences

Feb 25, 2025, 5:08 AM EST - 10 months ago

Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment

Feb 12, 2025, 2:40 PM EST - 10 months ago

Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 10:37 AM EST - 10 months ago

Alkermes Plc EPS Soars Past Forecasts

Feb 12, 2025, 7:00 AM EST - 10 months ago

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

Feb 5, 2025, 4:00 PM EST - 10 months ago

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

Jan 2, 2025, 4:00 PM EST - 11 months ago

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Quantumup Dec. 1 at 1:25 PM

B.Riley⬆️ $CNTA's PT to $42 from $33 and reiterated at a Buy rating after Data Deep Dive $ALKS $TAK $AVDL $ESALY HRMY Here's what B.Riley had to say:

0 · Reply

Otus Nov. 26 at 7:47 PM

0 · Reply

LarryYMB Nov. 26 at 6:37 PM

$ALKS this board is too boring , need some spice, it seems that the superior bid pushed away the danish fellas.

1 · Reply

prismmarketview Nov. 20 at 5:45 PM

0 · Reply

ZacksResearch Nov. 20 at 3:56 PM

0 · Reply

ZacksResearch Nov. 20 at 2:56 PM

0 · Reply

prismmarketview Nov. 19 at 3:07 PM

1 · Reply

LarryYMB Nov. 19 at 1:33 PM

$ALKS close the Avadel deal!

0 · Reply

OpenOutcrier Nov. 19 at 1:21 PM

$AVDL (-0.2% pre) $ALKS Alkermes increases Avadel acquisition offer to $22.50 per share https://ooc.bz/l/85063

0 · Reply

mikesterz7 Nov. 19 at 12:04 PM

$ALKS $AVDL Alkermes will now acquire Avadel for total transaction consideration of up to $22.50 per share.

0 · Reply

StocktwitsNews Nov. 19 at 11:35 AM

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge $AVDL $ALKS https://stocktwits.com/news/equity/markets/alkermes-to-acquire-avadel-for-up-to-2.37-billion-after-lundbeck-proposal/cLPoIyoREB2

0 · Reply

Quantumup Nov. 18 at 12:29 PM

Guggenheim⬆️ $CNTA's PT to $43 from $28 and reiterated at a Buy rating. $ALKS $TAK $ESALY $HRMY NCEL Guggenheim in its note said: Following the promising preliminary readout from the ORX750 CRYSTAL-1 Ph2a study across NT1 / NT2 / IH (analysis of the data & discussion with management), as well as the relatively underwhelming results from alixorexton in NT2 (ALKS), we are increasing our PT to $43 (prior $28). With ~$619M in pro forma cash following recent equity financing, we believe CNTA is well-positioned to progress ORX750 into pivotal trials for NT1 / NT2 / IH, which collectively represent ~185K patients in the US, by our estimates. ORX142 (currently in Ph1 HVs) and ORX489 (IND enabling), may further expand the addressable market of orexin agonists by targeting neurodegenerative and neuropsychiatric disorders.

0 · Reply

JarvisFlow Nov. 17 at 1:25 PM

Truist Securities has updated their rating for Alkermes ( $ALKS ) to Buy with a price target of 55.

0 · Reply

BEATOFtheMARKET Nov. 16 at 10:36 PM

$ALKS $ALLE $ALNY $ALV $AMAT

0 · Reply

Night_Owl_Biotech Nov. 14 at 11:29 PM

The Avadel transaction & SEC filing this AM provides new M&A valuation related data points This morning $AVDL filed its draft 14A with the SEC that included, among other things, the financial forecast provided $ALKS Coincidentally, this morning Lundberg $HLBBF offered $2.1B upfront for AVDL which was 4.0X AVDL's FY2029 (Year 4) revenue forecast and 0.37X AVDL's cumulative 10-year revenue forecast. AVDL did not provide a specific gross margin forecast but 9 month YTD gross margin was 92%. ALKS offered $1.85B which was 3.5X AVDL Year 4 revenue forecast & 0.33X its cumulative 10-year revenue forecast. All multiples exclude CVR potential By comparison, @ $16.62/share SNDX trades @ 1.5X FY2029 analyst estimates and 0.11X cumulative 10-year analyst estimates. We note AVDL here on SNDX because AVDL's offers were consistent with M&A multiples paid most peer ranging between 0.30 & 0.40X cumulative 10-year revenue forecasts and/or Year 4 multiples from 3.0 to 5.0X. This is not investment advice

1 · Reply

Cryptojoe9 Nov. 14 at 5:09 PM

$ALKS $30+ soon

1 · Reply

topstockalerts Nov. 14 at 1:39 PM

Avadel shares rose Friday after the company received an unsolicited takeover proposal from H. Lundbeck valuing it at up to $23 per share. The offer includes $21 in cash at closing plus a non-transferable CVR worth up to $2 based on U.S. sales milestones for LUMRYZ and valiloxybate: $1 if combined sales reach $450M by 2027, and another $1 if they hit $700M by 2030. The proposal follows Avadel’s October 22 agreement to be acquired by Alkermes for up to $20 per share, including $18.50 in cash and a $1.50 CVR tied to FDA approval of LUMRYZ for idiopathic hypersomnia by year-end 2028. Avadel’s board said the Lundbeck proposal could reasonably be considered a “Company Superior Proposal,” allowing discussions, though it hasn’t changed its recommendation on the Alkermes deal. Under Irish takeover rules, Lundbeck must announce a firm intention to bid—or walk away—no later than seven days before Avadel’s shareholder vote on the Alkermes transaction. $AVDL $ALKS

0 · Reply

OpenOutcrier Nov. 14 at 1:27 PM

$AVDL (+21.4% pre) Avadel (NASDAQ: AVDL) receives $23/share Lundbeck proposal, vs $20 $ALKS Alkermes deal https://ooc.bz/l/84547

0 · Reply

LarryYMB Nov. 14 at 1:11 PM

$ALKS go close the deal on Avadel, I am betting on you not fking this up!

1 · Reply

notreload_ai Nov. 14 at 12:36 PM

$AVDL receives unsolicited $23/share offer from Lundbeck, competing with existing $20/share $ALKS deal. Board reviewing superior proposal. https://notreload.xyz/avadel-gets-competing-bid-from-lundbeck/

0 · Reply

StocktwitsNews Nov. 14 at 11:19 AM

Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes $AVDL $ALKS https://stocktwits.com/news/equity/markets/avadel-gets-acquisition-proposal-from-lundbeck-weeks-after-inking-agreement-with-alkermes/cLPQetHRE4T

0 · Reply

JarvisFlow Nov. 13 at 3:43 PM

Wells Fargo updates rating for Alkermes ( $ALKS ) to Overweight, target set at 42 → 37.

0 · Reply

Market Cap	4.78B
Revenue (ttm)	1.56B
Net Income (ttm)	367.07M
EPS (ttm)	N/A
PE Ratio	14.03
Forward PE	17.10
Profit Margin	23.57%
Debt to Equity Ratio	0.00

Volume	593,291
Avg Vol	2,446,376
Day's Range	N/A - N/A
Shares Out	165.12M
Stochastic %K	70%
Beta	0.49
Analysts	Strong Sell
Price Target	$43.11